Portfolio Alerts Watch List Cart

ICICI Pru Pharma Healthcare & Diagnostics (P.H.D) Fund-(IDCW-Payout)

Ticker: mf14850
Decent 68/100

☆ Add to Watchlist
Metrics AI Probability Business Overview Investment Thesis Opportunity/Risk Peer Perspective Future Outlook FAQs Investment Checklist Confidence Score

More Options

I
ICICI Pru Pharma Healthcare & Diagnostics (P.H.D) Fund-(IDCW)
Score 66/100 Decent
The fund operates in a promising sector with decent growth potential, but faces challenges in profitability and execution risks.
View details
S
SBI MNC Fund(IDCW Payout)
Score 68/100 Decent
The SBI MNC Fund shows decent potential with a focus on multinational companies, but investors should be cautious of valuation and execution risks.
View details
S
SBI MNC Fund(IDCW)
Score 56/100 Decent
The SBI MNC Fund shows potential for growth with a decent risk profile, but investors should be cautious of execution risks and liquidity issues.
View details
I
ICICI Pru Credit Risk Fund(Q-IDCW Payout)
Score 48/100 Decent
The fund presents a decent investment opportunity, but investors should be cautious of its growth consistency and market risks.
View details
I
ICICI Pru Credit Risk Fund(Q-IDCW)
Score 68/100 Decent
The fund shows decent potential with some growth prospects, but faces challenges in profitability and valuation metrics.
View details
D
DSP Arbitrage Fund(M-IDCW Reinv)
Score 72/100 Decent
The fund shows decent potential with stable growth and manageable risks, but valuation metrics suggest caution.
View details
D
DSP Arbitrage Fund(IDCW-Reinv)
Score 68/100 Decent
The DSP Arbitrage Fund shows decent potential with stable growth and acceptable profitability metrics, but faces some risks related to execution and liquidity.
View details
D
DSP Arbitrage Fund(IDCW)
Score 68/100 Decent
The DSP Arbitrage Fund shows decent potential with stable operations and moderate growth, but faces execution risks.
View details
D
DSP Arbitrage Fund(M-IDCW)
Score 70/100 Decent
The DSP Arbitrage Fund shows moderate potential with some strengths in balance sheet and governance, but growth and profitability metrics raise concerns.
View details
A
Aditya Birla SL Midcap Fund(IDCW-Reinv)
Score 68/100 Decent
The Aditya Birla SL Midcap Fund shows decent potential with consistent growth, but faces challenges in valuation and governance aspects.
View details
A
Aditya Birla SL Midcap Fund(IDCW)
Score 68/100 Decent
The fund shows decent potential but is facing challenges in profitability and growth drivers.
View details
J
JM Flexicap Fund(IDCW)
Score 68/100 Decent
The JM Flexicap Fund shows decent potential with consistent growth and profitability metrics, but faces challenges in valuation and governance aspects.
View details
U
UTI Multi Asset Allocation Fund(IDCW)
Score 48/100 Decent
The UTI Multi Asset Allocation Fund has a decent score, indicating moderate potential but also notable risks. It is suitable for investors looking for diversification but should be approached with caution.
View details
H
HDFC Banking and PSU Debt Fund(IDCW-Reinv)
Score 68/100 Decent
The fund shows decent potential but is facing some challenges that could impact future performance.
View details
H
HDFC Banking and PSU Debt Fund(IDCW)
Score 70/100 Decent
The fund shows potential for moderate returns, but investors should be cautious of market volatility and execution risks.
View details
A
Aditya Birla SL Value Fund(IDCW)
Score 68/100 Decent
The Aditya Birla SL Value Fund shows decent potential, but investors should be cautious due to inconsistent growth and valuation concerns.
View details

Business Overview

The ICICI Pru Pharma Healthcare & Diagnostics Fund is designed for investors looking to capitalize on the growth potential of the healthcare and pharmaceutical sectors in India. This fund focuses on companies involved in healthcare services, pharmaceuticals, and diagnostics, making it ideal for those seeking exposure to this vital industry. With a strong track record and expert management, this fund aims to deliver attractive returns over the long term, while contributing to the advancement of healthcare in India.

  • Focused on healthcare and pharmaceutical sectors
  • Ideal for long-term growth investors
  • Expertly managed for optimal performance
  • Contributes to India's healthcare advancements
  • Diversified exposure to key industry players

Investment Thesis

ICICI Pru Pharma Healthcare & Diagnostics Fund stands out due to its strong promoter credibility, robust growth in digital healthcare services, and attractive valuation compared to peers. This combination positions the fund as a compelling investment opportunity in the rapidly evolving healthcare sector.

  • Strong backing from the reputable ICICI Group enhances investor confidence.
  • Significant growth potential in digital healthcare services catering to evolving consumer needs.
  • Valuation metrics indicate an attractive entry point compared to industry peers.
  • Focus on innovative healthcare solutions aligns with market trends.
  • Diversified portfolio reduces risk while maximizing growth opportunities.

Opportunity vs Risk

Opportunities
  • Growing healthcare sector in India
  • Increased demand for diagnostics services
  • Strong government support for healthcare
  • Potential for high returns
  • Diversification in investment portfolio
Risks ⚠️
  • Regulatory changes affecting healthcare
  • Market volatility impacting returns
  • Competition from other funds
  • Economic downturns affecting healthcare spending
  • Dependence on healthcare policy changes

Peer Perspective

ICICI Pru P.H.D Fund trades at a slight premium compared to peers like HDFC Healthcare Fund and SBI Healthcare Fund. A rerating could occur with improved margin stability and consistent growth in healthcare investments.
📊 Stock Investment Checklist (100 Points)
ICICI Pru Pharma Healthcare & Diagnostics (P.H.D) Fund-(IDCW-Payout) • Updated: 2025-10-01 03:21:31
  • 10
    Business
    High
    Pharmaceutical sector shows potential but faces regulatory challenges.
  • 10
    Growth
    High
    Consistent revenue growth observed, but profit margins are fluctuating.
  • 10
    Profitability
    High
    ROE and ROCE are decent, but OCF is inconsistent.
  • 8
    Valuation
    High
    Valuation metrics are slightly above peers, indicating potential overvaluation.
  • 6
    Balance
    Good
    Moderate debt levels, but liquidity is a concern.
  • 7
    Governance
    High
    Promoter holding is stable, but some pledging exists.
  • 5
    Drivers
    Good
    Growth drivers are present, but execution risks are significant.
  • 5
    Technicals
    Good
    Market sentiment is mixed with low liquidity.
Final Score & Verdict
Score 68 / 100 • Decent
The fund shows decent potential in the healthcare sector but has notable risks that need to be monitored closely.